Bis(thio-hydrazide amide) salts for treatment of cancers

A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula:

• wherein:
• Y is a covalent bond or a substituted or unsubstituted straight chained hydrocarbyl group;
• R1-R4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring;
• Z is —O or —S;
• and
• M+ is a pharmaceutically acceptable monovalent cation and M2+ is a pharmaceutically acceptable divalent cation.

A method of treating a subject with a cancer, said method comprising administering to the subject an effective amount of a compound represented by the following structural formula:

• wherein:
• Y is a covalent bond or a substituted or unsubstituted straight chained hydrocarbyl group;
• R1-R4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring;
• Z is —O or —S;
• and
• M+ is a pharmaceutically acceptable monovalent cation and M2+ is a pharmaceutically acceptable divalent cation.